In addition to advancing our own clinical pipeline in oncology, Cristal Therapeutics has forged a number of strategic partnerships with pharmaceutical and biotechnology companies to co-develop therapeutic nanomedicines and assess their applicability across a number of therapeutic areas.
CPC 634
We plan to partner / out-license CPC634, our lead product candidates after Phase 2 studies to pharmaceutical companies with late stage development and commercialisation capabilities in attractive geographic territories.
Inflammation program
In addition CPC289, the therapeutic asset from our inflammation program is ready for pre-clinical development and is available for out-licensing.
Our CliCr® technology platform: ready to connect
Suitable for generating superior and novel conjugate products including bioconjugate-based therapeutics, nanomedicines, biomaterials and diagnostics, our proprietary click chemistry platform is available for testing through joint proof of concept studies with further development under a license.
Partnering opportunities
To find out more about partnering opportunities,
email: partnering@cristaltherapeutics.com
or use the form below.
© Cristal Therapeutics
Oxfordlaan 55
6229 EV Maastricht
Netherlands
